Boehringer Ingelheim (BI), headquartered in Germany, has commenced the expansion of its manufacturing facility in Greece as part of a strategic plan initiated in 2020 to enhance production capacity. This EUR 120 million investment aims to bolster the supply of medications to the US market, with a particular focus on the SGLT2 inhibitor Jardiance (empagliflozin), which is indicated for type 2 diabetes (T2D), chronic heart failure, and chronic kidney disease (CKD).
The upgraded facility will not only produce Jardiance but will also support the manufacturing of existing medications and future product launches currently in the late stages of development. These will span various therapeutic areas, including cardio-renal-metabolic (CRM) diseases, mental health, pulmonary fibrosis, systemic sclerosis, and chronic liver disease.- Flcube.com
